Most Read

VE416 is Vedanta Biosciences’ live biotherapeutic product candidate being developed for treatment of food allergies, including persistent peanut allergy. The study, which is being conducted at MassGeneral Hospital

“We are delighted by this outcome which we regard as an important stage for Sensorion and young patients. Indeed, this approval will allow Sensorion to develop SENS-401 for

Post-bariatric hypoglycemia (PBH) is a complication of bariatric surgery thought to be related to excessive insulin secretion in response to a meal. PBH can begin to occur one

IMB-115 is an internally discovered compound with a novel mechanism of action in clinical development for the treatment of insomnia disorders, including insomnia associated with alcohol cessation (IAAC).

Programmed death-ligand 1 (PD-L1) is a transmembrane protein that plays a major role in suppressing the immune system in many cancer patients. The binding of PD-L1 to the

This program will be the first of its kind in the San Francisco Bay Area, which serves as a hub of both tech and biotech industries and is

SUSHI study achieved the primary endpoint of safety and tolerability, and also demonstrated efficacy trends in favor of RBM-007. Subjects recruited for the SUSHI Study had wet AMD

University of California San Diego (UCSD) Health is the initial and lead center for the Phase 1 clinical trial under the leadership of Eric Adler, M.D., Director of

RVVC is also known as chronic yeast infection and is often accompanied by severe physical discomfort and emotional burden. Mycovia is currently conducting global Phase 3 trials of